. Author manuscript; available in PMC: 2022 May 1.

Published in final edited form as: Transplant Cell Ther. 2021 Feb 25;27(5):405.e1–405.e6. doi: 10.1016/j.jtct.2021.02.026

Table 3.

Characteristics of stem cell boost population (n = 10, including one patient who required two stem cell boosts)

Characteristic			Median (range)
Age, years			62 (47–72)
Response status prior to first ASCT	SD		1
	PR		5
	CR/VGPR		4
CD34+ dose at ASCT (x 10⁶/kg)			3.1 (1.8–18)
Day of stem cell boost after ASCT			35 (17–81)
Stem cell boost dose (CD34+ cells × 10⁶/kg)			5.6 (1.9–20)
Day of engraftment following stem cell boost		Neutrophil	4 (2–11)
		Hemoglobin	15 (4–34)
		Platelet	12 (0–34)
			Number of patients
Indication for boost		Delayed engraftment	6
		Non-engraftment	4 (including 1 patient who required second boost for delayed engraftment)
		New pancytopenia	1

Table abbreviations: ASCT = autologous stem cell transplant; SD = stable disease, VGPR = very good partial response; PR = partial response; CR = complete response; PD = progressive disease